News Related to Primary Immune Thrombocytopenia

Related coverage linked through entity extraction aliases.

argenx Reports $1.3B Q1 2026 Revenue, PDUFA Date Set for May 10 in Seronegative gMG

May 07, 2026

argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.

Novartis Reports Final ALIGN Trial Data Showing Vanrafia Slows Kidney Decline in IgAN

Feb 16, 2026

Novartis announced final Phase III ALIGN trial results showing Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy, with a 2.39ml/min/1.73m² eGFR difference versus placebo at week 136.